Relmada advancing depression med, mid-stage data readout this quarter

Relmada Therapeutics (OTCQB:RLMD -0.4%) announces that the last participant has been dosed in a Phase 2 clinical trial evaluating REL-1017 (dextromethadone) for the adjunctive treatment of patients with treatment-resistant depression. Topline data should be available later this quarter.

REL-1017 is an orally administered NMDA receptor antagonist. The company says it does not have the unwanted psychomimetic side effects of ketamine. It has Fast Track status in the U.S. for the adjunctive treatment of major depressive disorder.

https://seekingalpha.com/news/3482775-relmada-advancing-depression-candidate-relminus-1017-mid-stage-data-readout-quarter